Dexcom Inc
NASDAQ:DXCM

Watchlist Manager
Dexcom Inc Logo
Dexcom Inc
NASDAQ:DXCM
Watchlist
Price: 80.24 USD 0.88% Market Closed
Market Cap: 31.3B USD
Have any thoughts about
Dexcom Inc?
Write Note

Dexcom Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dexcom Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Dexcom Inc
NASDAQ:DXCM
Cash from Operating Activities
$821.7m
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
45%
Becton Dickinson and Co
NYSE:BDX
Cash from Operating Activities
$3.8B
CAGR 3-Years
-6%
CAGR 5-Years
3%
CAGR 10-Years
8%
Boston Scientific Corp
NYSE:BSX
Cash from Operating Activities
$2.9B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
10%
Stryker Corp
NYSE:SYK
Cash from Operating Activities
$3.8B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Cash from Operating Activities
$8.7B
CAGR 3-Years
-8%
CAGR 5-Years
10%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash from Operating Activities
$1.8B
CAGR 3-Years
-5%
CAGR 5-Years
6%
CAGR 10-Years
10%
No Stocks Found

Dexcom Inc
Glance View

Market Cap
31.3B USD
Industry
Health Care
Economic Moat
Narrow

Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.

DXCM Intrinsic Value
44.01 USD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Dexcom Inc's Cash from Operating Activities?
Cash from Operating Activities
821.7m USD

Based on the financial report for Sep 30, 2024, Dexcom Inc's Cash from Operating Activities amounts to 821.7m USD.

What is Dexcom Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
45%

Over the last year, the Cash from Operating Activities growth was 10%. The average annual Cash from Operating Activities growth rates for Dexcom Inc have been 17% over the past three years , 32% over the past five years , and 45% over the past ten years .

Back to Top